References: |
Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis,systemic lupus erythematosus, ulcerative colitis. For the detailed information of Solcitinib(GLPG0778,GSK2586184), the solubility of Solcitinib(GLPG0778,GSK2586184) in water, the solubility of Solcitinib(GLPG0778,GSK2586184) in DMSO, the solubility of Solcitinib(GLPG0778,GSK2586184) in PBS buffer, the animal experiment (test) of Solcitinib(GLPG0778,GSK2586184), the cell expriment (test) of Solcitinib(GLPG0778,GSK2586184), the in vivo, in vitro and clinical trial test of Solcitinib(GLPG0778,GSK2586184), the EC50, IC50,and affinity,of Solcitinib(GLPG0778,GSK2586184), For the detailed information of Solcitinib(GLPG0778,GSK2586184), the solubility of Solcitinib(GLPG0778,GSK2586184) in water, the solubility of Solcitinib(GLPG0778,GSK2586184) in DMSO, the solubility of Solcitinib(GLPG0778,GSK2586184) in PBS buffer, the animal experiment (test) of Solcitinib(GLPG0778,GSK2586184), the cell expriment (test) of Solcitinib(GLPG0778,GSK2586184), the in vivo, in vitro and clinical trial test of Solcitinib(GLPG0778,GSK2586184), the EC50, IC50,and affinity,of Solcitinib(GLPG0778,GSK2586184), Please contact DC Chemicals. |